GLP-1 Weight-Loss Plateau: Why It Happens, When to Expect It, and What the Evidence Says to Do

The plateau is in the trials

Every pivotal trial of these drugs has the same shape: steep loss for six to nine months, a slowing, and a flattening between roughly month 9 and month 18. In SURMOUNT-1, most of the 20.9% loss at 15 mg was achieved by week 52; the difference between week 52 and week 72 was small. In STEP 1, semaglutide's curve flattened after about week 60. STEP 5, which ran semaglutide for two years, found that the 15.2% loss at week 104 was essentially the same as the loss at week 68: maintained, not extended. Patients who expect the curve to continue downward indefinitely are expecting something no trial has shown.

Why it happens

Energy expenditure falls with weight. A smaller body needs fewer calories to run and to move. Resting energy expenditure drops by roughly 10 calories per day per pound lost, and the energy cost of activity drops with it. A patient who has lost 50 pounds needs several hundred fewer calories a day than at baseline. The intake reduction that produced a large deficit at the start produces a small deficit, then none.

Adaptive thermogenesis. Beyond the expected drop, energy expenditure falls further than body composition predicts, by an additional 5 to 15% in most studies, as the body defends its previous weight. This effect persists as long as weight is below the previous set point.

The appetite ceiling. GLP-1 and GIP agonism reduce appetite by a bounded amount. The drug does not keep reducing intake indefinitely; it reduces it to a new level, and once expenditure falls to meet that level, loss stops. This is why the plateau weight depends on dose: SURMOUNT-1's 5 mg arm plateaued around 15% and the 15 mg arm around 21%.

Intake creep. Over months, patients adapt to the drug's effect. Meal sizes drift up, snacks return, calorie-dense foods that were unappealing become tolerable. Self-reported intake at month 12 is typically higher than at month 3, and the difference is enough to close a small deficit.

Lean-mass loss. About a quarter to two-fifths of weight lost is lean mass, which is metabolically active. Preserving it with protein and resistance training keeps expenditure higher and the plateau later.

What to check before changing anything

Dose. Are you at the maximum dose you tolerate? Many telehealth patients are held at 5 or 7.5 mg of tirzepatide, or 1 mg of semaglutide, for tolerability or by provider policy, and a plateau at those doses is a plateau at a sub-maximal dose. The SURMOUNT-1 dose-response is clear: 15.0% at 5 mg, 19.5% at 10 mg, 20.9% at 15 mg. If you are below the top dose and tolerate it, escalation is the first step.

Intake. Two weeks of honest tracking, using the calorie tool for a target, will usually show whether intake has drifted. It often has.

Protein and resistance training. If lean mass has been lost, expenditure has fallen faster than it needed to. The protein and water tool gives targets; two to three resistance sessions a week is the evidence-based dose.

Sleep. Short sleep raises ghrelin, lowers leptin, and increases intake in controlled studies. Less than six hours is a modifiable cause of a stall.

Alcohol. Calories, disinhibition, and worse sleep. Most GLP-1 patients drink less; those who do not often plateau earlier.

Medications. Antipsychotics, some antidepressants, insulin, sulfonylureas, corticosteroids, beta-blockers and some antihistamines promote weight gain. A review with the prescriber may find a substitute.

Thyroid, menopause, fluid. Hypothyroidism should be excluded once. Menopause shifts fat distribution and energy expenditure. Fluid retention from salt, cycle phase or new exercise can mask fat loss for weeks; measure waist and use a monthly average.

The options with evidence

Escalate to the maximum tolerated dose. Discussed above; the most effective single step for patients below it.

Switch from semaglutide to tirzepatide. No trial has randomized plateaued semaglutide patients to switch, but SURMOUNT-5 (20.2% versus 13.7%) and SURPASS-2 (in diabetes) establish that tirzepatide produces more loss at maximum doses, and clinical experience is that switching after a semaglutide plateau usually produces additional loss, often 5 to 10% more. The switch is done one week after the last semaglutide dose, starting tirzepatide at 2.5 or 5 mg depending on the semaglutide dose reached and tolerability, then escalating. It requires a prescriber; do not overlap the drugs. The cost difference through telehealth is $20 to $40 per month.

Add intensive lifestyle intervention. SURMOUNT-3 showed that tirzepatide after a 12-week intensive lifestyle program produced an additional 18.4% loss; the combination outperformed either alone. A structured program with a dietitian, or a provider whose membership includes one, is a reasonable step for a plateaued patient who has not had one.

Higher semaglutide dose. Semaglutide 7.2 mg produced 20.7% loss at 72 weeks in STEP UP and was approved in Europe in 2025; it is under FDA review. When approved in the US it will be an option for patients plateaued at 2.4 mg who prefer to stay on semaglutide.

Combination therapy. Adding metformin, bupropion-naltrexone, topiramate or an SGLT2 inhibitor to a GLP-1 is done in obesity-medicine practice with modest additional loss and no large trials. Providers such as Found prescribe from that menu.

Accept maintenance. A patient who has lost 15 to 20% and plateaued has achieved the trial-typical outcome, and for most of the health benefits (blood pressure, lipids, glycemia, sleep apnea, joint pain) that is the therapeutic goal. The evidence on stopping is unambiguous: SURMOUNT-4 and STEP 4 show regain of most of the loss within a year. The plateau is not the moment to stop; it is the moment the goal changes from losing to holding. The maintenance article covers what that involves.

What does not have evidence

"Microdosing" to reset sensitivity, drug holidays to restore response, cycling on and off, and supplement stacks marketed for plateaus have no trial support. The dose-response argues against the first; SURMOUNT-4 argues against the second and third. Providers selling them are selling something the science does not support, and the microdosing article explains what is and is not known.

A realistic timeline

Expect the first slowdown around month six, a clear flattening between months nine and fifteen, and a plateau weight roughly 15 to 22% below baseline on tirzepatide at 15 mg or 12 to 17% below on semaglutide at 2.4 mg, with wide individual variation. If you plateau earlier or higher, work through the checks above in order. If you plateau at the trial-typical loss, you are where the trials say you should be, and the work becomes keeping it.

Sources

1. Jastreboff AM et al. SURMOUNT-1. N Engl J Med 2022;387:205-216 (weight-change curves).
2. Wilding JPH et al. STEP 1. N Engl J Med 2021;384:989-1002.
3. Garvey WT et al. STEP 5. Nat Med 2022;28:2083-2091.
4. Aronne LJ et al. SURMOUNT-5. N Engl J Med 2025.
5. Frías JP et al. SURPASS-2. N Engl J Med 2021;385:503-515.
6. Hall KD, Kahan S. Maintenance of Lost Weight and Long-Term Management of Obesity. Med Clin North Am 2018;102:183-197.
7. Wadden TA et al. SURMOUNT-3. Nat Med 2023;29:2909-2918.
8. Aronne LJ et al. SURMOUNT-4. JAMA 2024;331:38-48.

Citations are to primary sources (peer-reviewed trials, FDA labeling and announcements, and provider pricing pages). See our sources policy and corrections log.